KESTREL Trial Testing Durvalumab With or Without Tremelimumab in HNSCC Misses OS End Points
Investigators of the phase 3 KESTREL trial recruited 823 patients with previously untreated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).